Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06844214 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
A Phase 1 study of Myotonic Dystrophy, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 8
- Study locations
NCT06844214 is a Phase 1 study of Myotonic Dystrophy that is actively recruiting participants, run by Sanofi. The registered enrollment target is 32 participants, below the 852-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT06844214, a Phase 1 study of Myotonic Dystrophy, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 50 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268. The study consists of a dose escalation part (Part A) during which single ascending doses of SAR446268 will be evaluated in 3 distinct cohorts and an optional 4th dose cohort. Once a safe and effective dose is identified, additional participants will be treated in Part B, the dose expansion phase of the study. The study duration will be 110 weeks (approximately 2 years) for each participant in Parts A and B respectively and includes a 6-week screening phase and a 104-week follow-up period post-SAR446268 administration.
Conditions Studied
Interventions
- BIOLOGICAL SAR446268
Study Locations (8)
Other
- Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190 - Site Number: 0320001 - Buenos Aires
- Investigational Site Number : 3760002 - Ramat Gan
- Investigational Site Number : 8260002 - Newcastle upon Tyne
Florida
- University of Florida, 2004 Mowry Road - Site Number: 8400005 - Gainesville
- University of South Florida - Neuromuscular Research, 13330 USF Laurel Drive - Site Number: 8400001 - Tampa
New York
- Columbia University Medical Center - Neurological Institute, 710 W. 168th, 2nd floor, suite 204 - Site Number : 8400003 - New York
Queensland
- Investigational Site Number : 0360001 - Brisbane
Quebec
- The Montreal Neurological Institute and Hospital, 3801 rue University - Site Number: 1240001 - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06844214
The ClinicalTrials.gov registry entry for NCT06844214 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 852-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (96% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myotonic Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which SAR446268 is the first listed.
NCT06844214 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06844214 about?
NCT06844214 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1". This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 50 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR4462...
What is the current status of trial NCT06844214?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-07-23. Estimated completion is 2029-02-28.
What conditions does trial NCT06844214 study?
This clinical trial studies the following conditions: Myotonic Dystrophy.
What interventions are being tested in trial NCT06844214?
The interventions under investigation include: SAR446268 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06844214?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06844214 being conducted?
This trial has 8 study locations across Florida, New York, Queensland, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
COMPLETED · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
RECRUITING
-
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RECRUITING
-
Extracellular RNA Biomarkers of Myotonic Dystrophy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.